Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 1,001–1,026 of 1,026
Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1682 · Cited by 42
Self-citationDewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1867 · Cited by 41
Self-citationHaufe, S., Kaminski, J., Utz, W., Haas, V., Mähler, A., Daniels, M. A., Birkenfeld, A. L., Lichtinghagen, R., Luft, F. C., Schulz-Menger, J., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000573 · Cited by 41
“In contrast, chronic pharmacological natriuretic peptide augmentation through angiotensin–neprilysin inhibition improved mortality in heart failure patients [10].”
BackgroundPascual-Figal, D., Wachter, R., Senni, M., Bao, W., Noè, A., Schwende, H., Butylin, D., Prescott, M. F., Gniot, J., Mozheiko, M., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.05.012 · Cited by 38
“In patients with HF and reduced ejection fraction (HFrEF), a greater N-terminal pro– B-type natriuretic peptide (NT-proBNP) reduction in response to sacubitril/valsartan administration than to enalapril has been observed in ambulatory patients (PARADIGM-HF [Prospective Comparison of ARNI with ACEI to Determine Impact…”
BackgroundContemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies
Vaduganathan, M., Butler, J., Pitt, B., & Gheorghiade, M. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002271 · Cited by 38
“For instance, in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, SBP trajectory as a time-varying covariate was not a determinant of benefit of sacubitril/valsartan compared with enalapril.(13)”
BackgroundResultInfluentialKiuchi, M. G., Ho, J. K., Nolde, J. M., Gavidia, L. M. L., Carnagarin, R., Matthews, V. B., & Schlaich, M. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01546 · Cited by 36
Ghanim, H., Monte, S., Caruana, J., Green, K., Abuaysheh, S., & Dandona, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13320 · Cited by 36
“In addition, it has been shown that its inhibition by sacubitril leads to improved outcomes in congestive cardiac failure.(7) In this study, we investigated if RYGB surgery and the associated weight loss results in a decrease in neprilysin and an increase in vaso-”
BackgroundHealth‐related quality of life outcomes in PARAGON‐HF
Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2738 · Cited by 33
Self-citationDilated Cardiomyopathy: From Genetics to Clinical Management
(2019) · doi:10.1007/978-3-030-13864-6 · Cited by 32
Gronda, E., Vanoli, E., Sacchi, S., Grassi, G., Ambrosio, G., & Napoli, C. (2020) · Heart Failure Reviews · doi:10.1007/s10741-019-09823-z · Cited by 30
Abdul-Rahim, A. H., MacIsaac, R. L., Jhund, P. S., Petrie, M. C., Lees, K. R., & McMurray, J. J. V. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.074 · Cited by 29
Self-citationDesai, R. J., Levin, R., Lin, K. J., & Patorno, E. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016906 · Cited by 29
Serum potassium and heart failure: association, causation, and clinical implications
Sfairopoulos, D., Arseniou, A., & Korantzopoulos, P. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10039-9 · Cited by 23
Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor
Smith, G. A., Padmanabhan, A., Lau, B. H., Pampana, A., Li, L., Lee, C. Y., Pelonero, A., Nishino, T., Sadagopan, N., Xia, V. Q., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj8670 · Cited by 23
Arginine vasopressin antagonism in heart failure: Current status and possible new directions
Goldsmith, S. R. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.03.001 · Cited by 22
Bouabdallaoui, N., O'Meara, E., Bernier, V., Komajda, M., Swedberg, K., Tavazzi, L., Borer, J. S., Bohm, M., Ford, I., & Tardif, J.-C. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12513 · Cited by 21
Self-citationCOVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?
Pallarés Carratalá, V., Górriz-Zambrano, C., Morillas Ariño, C., Llisterri Caro, J. L., & Gorriz, J. L. (2020) · Medicina de Familia. SEMERGEN · doi:10.1016/j.semerg.2020.05.005 · Cited by 21
Continuation of chronic heart failure therapies during heart failure hospitalization—a review
Singhania, G., Ejaz, A. A., McCullough, P. A., Kluger, A. Y., Balamuthusamy, S., Dass, B., Singhania, N., & Agarwal, A. (2019) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2019.03.562 · Cited by 20
“…of angiotensin II receptor blockers - neprilysin inhibitor (ARNI or sacubitril/valsartan) were shown in the Prospective Comparison of ARNI With an ACE Inhibitor to Determine Impact on Global Mortality and Morbidity in HF (PARADIGM-HF) double blind RCT (n = 8,442 patients) (Mc- murray et al., 2014).”
MethodThe Potential Role of Renal Denervation in the Management of Heart Failure
Kassab, K., Soni, R., Kassier, A., & Fischell, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144147 · Cited by 19
“Large scale clinical trials, such as PARADIGM-HF, demonstrated that combining a neprilysin inhibitor (Sacubitril) with valsartan was superior to the standard guideline-directed therapy with a RAAS inhibitor alone (enalapril) [33].”
Zhang, S., Raedschelders, K., Santos, M., & Van Eyk, J. E. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00482 · Cited by 19
Women and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Correale, M., Mazzeo, P., Tricarico, L., Croella, F., Fortunato, M., Magnesa, M., Amatruda, M., Alfieri, S., Ferrara, S., Ceci, V., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01166-2 · Cited by 14
“Sacubitril/valsartan has been shown to improve clinical outcomes in patients with HFrEF [83].”
BackgroundGrant, A. D. M., Chew, D. S., Howlett, J. G., & Miller, R. J. H. (2020) · CJC Open · doi:10.1016/j.cjco.2020.05.009 · Cited by 12
“0091 Beta McMurray et al.(5) HF hospitalization HR (sacubitril/ valsartan vs enalapril) 0.”
BackgroundMethodInfluentialCathepsin A Inhibitors to Treat Heart Disease
Cowling, R. T. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.004 · Cited by 8
“, the PARADIGM-HF [Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial) (11).”
MethodNovel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation
(2023) · doi:10.1111/bph.16203 · Cited by 5
“Valsartan / sacubitril is a combination of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril and has been shown to be effective in the treatment of chronic heart failure (McMurray et al., 2014).”
BackgroundSepehrvand, N., & Ezekowitz, J. A. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002126 · Cited by 3
“Currently approved HF therapies that are in widespread use have taken advantage of the minimally clinically important difference of ≥5 points for the KCCQ, and this benchmark offers unique insight into clinical trial results.(6,7,17,18) For example, in early clinical trials enrolling highly symptomatic patients with H…”
Background
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.